Perceive Biotherapeutics, Inc.
PrivateLast Round
Series B
Jan 5, 2023
Total Funding Raised
$78M
Momentum
Top 50%
of companies Caplight tracks
Company Overview
Perceive Biotherapeutics, Inc. is a biotechnology company that develops gene therapies and other innovative therapeutics for the treatment of ocular diseases such as age-related macular degeneration and glaucoma.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Clinical Trials, Drug Discovery
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Perceive Biotherapeutics, Inc. Comparables
Compare Perceive Biotherapeutics, Inc. with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Atsena Therapeutics | 88% | |
| Beacon Therapeutics | 87% | |
| Opus Genetics | 87% |
Perceive Biotherapeutics, Inc. Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | Jan 5, 2023 | ||||
| Series A | Aug 1, 2018 |
Key People
Founding team and executive leadership
Perceive Biotherapeutics, Inc. Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Deerfield Management | Series A, Series B |
| Braidwell | Series B |
| Catalio Capital Management | Series B |
| Foundation Fighting Blindness | Series B |
| Johnson & Johnson Innovation – JJDC | Series B |
| Johnson & Johnson Innovation - JJDC, Inc. | Series B |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jun 20, 2026
Monthly visitors increased 98% MoM.
- Dec 1, 2025
Lead gene therapy program in ophthalmology enters Phase 2 trials.
Recent news
Latest coverage and updates
- hiresOct 9, 2026
Perceive Bio appoints Tony Gibney to its board of directors as an independent director on Oct 12th '26, adding his more than 30 years of biotechnology finance, corporate strategy, and business development experience.
Perceive Biotherapeutics, Inc. Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Perceive Biotherapeutics, Inc.'s valuation, stock price, and market status.
Is Perceive Biotherapeutics, Inc. a public or private company?
Perceive Biotherapeutics, Inc. is a private company.
What is the current stock price of Perceive Biotherapeutics, Inc.?
Perceive Biotherapeutics, Inc. is a private company, so its shares have no public market price. Caplight tracks Perceive Biotherapeutics, Inc.'s secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Perceive Biotherapeutics, Inc. worth (valuation)?
Valuation information for Perceive Biotherapeutics, Inc. is not publicly available.
Can I buy Perceive Biotherapeutics, Inc. stock?
Perceive Biotherapeutics, Inc. shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Perceive Biotherapeutics, Inc.'s last funding round?
Perceive Biotherapeutics, Inc.'s most recent funding round was Series B on January 5, 2023.
Who are the main investors in Perceive Biotherapeutics, Inc.?
Key investors in Perceive Biotherapeutics, Inc. include Deerfield Management, Johnson & Johnson Innovation – JJDC, Johnson & Johnson Innovation - JJDC, Inc..
Will Perceive Biotherapeutics, Inc. IPO soon?
No public IPO plans have been announced for Perceive Biotherapeutics, Inc..
How can I track Perceive Biotherapeutics, Inc. secondary market activity?
Caplight tracks bids, offers, and trades in Perceive Biotherapeutics, Inc.'s shares on secondary markets.